Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
154.9 EUR | -5.39% |
|
-4.41% | +14.59% |
05:51am | Chemical industry wage partners seek solution before the end of the peace period | DP |
06-25 | German Stocks Fall Tuesday | DJ |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- With a 2024 P/E ratio at 22.91 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company's enterprise value to sales, at 3.51 times its current sales, is high.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+14.59% | 73.29B | - | ||
+17.03% | 9.11B | A- | ||
-24.00% | 4.44B | A- | ||
+13.37% | 4.24B | B- | ||
+31.17% | 4.03B | - | ||
+7.93% | 2.14B | B | ||
-34.04% | 1.9B | C- | ||
+7.56% | 1.94B | - | - | |
-0.50% | 1.64B | - | - | |
-47.93% | 1.63B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MRK Stock
- MRCK Stock
- Ratings Merck KGaA